Windfalls And Collateral Damage In Pfizer/Allergan Tie-Up
This article was originally published in Scrip
Executive Summary
In announcing their $160bn agreement to merge Pfizer and Allergan, CEOs Ian Read and Brent Saunders threw a huge figurative stone into a global pond of companies, governments, patients, prescribers, healthcare payers, employees, consumers, academic institutes and more – let's call them "stakeholders". With the deal not scheduled to close until the second half of 2016, we will no doubt spend months and even years observing the splash and its myriad ripple effects on this multifarious ecosystem.